个人简历

学习经历 2004.09-2009.06 黑龙江中医药大学 药学院 生药学（硕博连读） 博士学位 2000.09-2004.07 黑龙江中医药大学 药学院 中药学 学士学位 工作经历 2016.09-至今 上海交通大学系统生物医学研究院 研究员/课题组长/博导 2013.07-至今 QUT Vice Chancellor’s Fellowship (国际人才基金，Adjunct Faculty） 2012.09-2016.09 重庆大学药学院（创新药物研究中心）百人计划研究员/博导/主任助理 2009.09-2013.01 美国爱因斯坦医学院/华盛顿大学医学院/麻省理工学院 博士后研究员

研究领域

1. 精准修饰代谢组学 2. 微生物代谢 3. 中药系统生物学

近期论文

1. Luo, X., Guo, R., Xu, X., Li, X., Yao, L., Wang, X., and Lu, H*. (2018). Spectrometry And Associated Technologies Delineate The Advantageously Biomedical Capacity Of SiderophoresIn Different Pathogenic Contexts. Mass Spectrometry Reviews, doi: 10.1002/mas.21577(Invited by Editor in Chief)(*Corresponding Author) 2. Su, Q, Xu, G. Guan, T. Que, Y. and Lu, H*. (2018). Mass spectrometry-derived systems biology technologies delineate the system's applications of siderophores with chemistry and biology. Mass Spectrometry Reviews, 37, 188-201(Invited by Editor in Chief) (*Corresponding Author) 3. Su, Q., Guan, T. B., He, Y. and Lv, H*. (2016). Siderophore biosynthesis governs the virulence of uropathogenic Escherichia coli by coordinately modulating the differential metabolism. Journal of Proteome Research, 15, 1323-1332. (*Corresponding Author) 4. Nie, W.N., Yan, L. Y. Lee, Y. H., Guha, C., Kurland, I. J., and Lu, H.T.,* (2016). Advanced mass spectrometry based multiple omics technologies for exploring the pathogenesis of hepatocellular carcinoma. Mass Spectrometry Reviews, 35, 331-349. (*Corresponding Author) 5. Nie, W., Lv, Y., Yan, L., Chen, X. and Lv, H*. (2015): Prediction and Characterization of the System Effects of Aristolochic Acid: A Novel Joint Network Analysis towards Therapeutic and Toxicological Mechanisms. Scientific Reports 5, 17646; doi: 10.1038/srep17646. (*Corresponding Author) 6. Lv, H. T*., Hung, C. S., and Henderson, J. P.* (2014): Metabolomic Analysis of Siderophore Cheater Mutants Reveals Metabolic Costs of Expression in Uropathogenic Escherichia coli. Journal of Proteome Research, 13, 1397-1404. (*Corresponding Author) 7. Lv, H. T.* (2013): Mass spectrometry based metabolomics towards understanding of gene functions with a diversity of biological contexts, Mass Spectrometry Reviews, 32, 118-128. (*Corresponding Author) 8. Lv, H.T., and Henderson, J. P. (2011): Yersinia High Pathogenicity Island genes modify the Escherichia coli primary metabolome independently of siderophore production. Journal Proteome Research, 10, 5547-5554. 9. Lv, H.T., Palacios, G., Hartil, K. and Kurland, I.J. (2011): Advantages of Tandem LC-MS for the Rapid Assessment of Tissue-specific Metabolic Complexity using a Pentafluorophenylpropyl Stationary Phase. Journal Proteome Research, 10, 2104-2012. 10. Lv, H.T*., Hung, C. S., Chaturvedi, K. S., Hooton, T. M., and Henderson, J.P.* (2011): Development of an integrated metabolomic approach for Infectious Diseases Research. Analyst, 136, 4752-4763. (*Corresponding Author) 11. Yan, L. Y., Nie, W. N., and Lv, H. T. * (2015) Metabolic Phenotyping of the Yersinia High-Pathogenicity Island that Regulates Central Carbon Metabolism. Analyst, 140, 3356-3361. (*Corresponding Author) 12. Lv, H.T*., Liu, L., Palacios, G. and Chen, X. (2011): Metabolomic Analysis Characterizes Tissue Specific Metabolic Perturbations of the Rats Induced by Indomethacin. Analyst, 136, 2260-2269. (*Corresponding Author) 13. Nie, W. N., Lv, Y. N., Yan, L. Y., Guan, T. B., Li, Q., Guo, X. J., Liu, W. H., Feng, M. P., Xu, G., Chen, X., Lv, H. T. * (2015) Discovery and Characterization of Disease Risk Functional Modules and Pathogenic Genes of Coronary Artery Disease. RSC Advances, 5, 26443-26451. (*Corresponding Author) 14. Lv, Y., Que, Y., Su, Q., Li, Q., and Lu, H*. (2016). Bioinformatics facilitating the use of microarrays to delineate potential miRNA biomarkers in aristolochic acid nephropathy. Oncotarget, doi: 10.18632/oncotarget.10586. (*Corresponding Author) 15. Su, Q., Guan, T. and Lv, H*. (2016) Siderophore biosynthesis coordinately modulated the virulence associated interactive metabolome of uropathogenic Escherichia coli and human urine. Scientific Reports, 6, 24099; doi: 10.1038/srep24099 (*Corresponding Author) 16. Liu, W. H., Guo, X. J., Li, Q., Xu, G., Feng, M. P., Guan, T. B., Yan, L. Y., Nie, W. N., Parker, T., Lv, H. T. * Mass Spectrometry Based Molecular Profile Dissects The Complexity of Traditional Chinese Medicine. Anal Methods, 2015, 7, 2902-2912. (*Corresponding Author) 17. Wang, X.J*., Lv, H.T., Zhang, A. H., Wenjun Sun, Liu, L., Wang, P., Wu, Z.M., Zhou, D. X., Sun, H. * (2013) Metabolite profiling and pathway analysis of acute hepatitis rats by UPLC-ESI MS combined with pattern recognition methods. Liver International, 34, 759-770. 18. Wang. X.J.,* Zhang, A.H., Wang, P., Sun, H., Wu, G., Sun, W.J., Lv, H.T., et al. (2013): Metabolomics coupled with proteomics advancing drug discovery towards more agile development of targeted combination therapies. Mol Cell Proteomics. 12, 1226-1238. 19. Yan, L. Y., Nie, W.N., Parker, T., Upton, Z., Lv, H. T. * (2013) Mass spectrometry based metabolomics facilitates the discovery of in vivo functional small-molecules with a diversity of biological contexts. Future Medicinal Chemistry, 5, 1953-1965. (*corresponding author)